Board Meeting
Outcome of Board Meeting
Par Drugs and Chemicals LimitedPAR · Filed with the exchange
Par Drugs' board met.
Approved FY26 annual results: Revenue ₹103.66 Cr, PAT ₹13.11 Cr.
Key approvals include higher remuneration for MD, CEO (₹0.64 Cr each), & Ind.
Director (₹0.24 Cr), all subject to shareholder vote.
MD/CEO now authorized for investment management.
No comments yet. Be the first.